Health and Healthcare

Tuesday's Top Biotech & Medical Stocks

From BioHealth Investor

by H.S. Ayoub
BioHealth Investor.com

Biotechnology

NUVELO INC NEW [NUVO] +24.92%
NEOSE TECH INC [NTEC] +20.67%
CARDIOVASCULAR BIOTH [CVBT.OB] +18.18%
CV THERAPEUTICS I [CVTX] +17.93%
REGENERON PHARMACE [REGN] +14.88%

Diagnostic Substances

AVANT IMMUNOTHERAP [AVAN] +10.53%
QUIDEL CP [QDEL] +7.43%
AMER BIO MEDICA [ABMC] +7.02%
SCOLR PHARMA INC [DDD] +6.38%
ORCHID CELLMARK INC [ORCH] +6.30%

Drug Delivery

NOVADEL PHARMA INC [NVD] +6.06%
NEKTAR THERAPEUTIC [NKTR] +2.44%
COLUMBIA LABS INC [CBRX] +2.22%
BIOPROGRESS PLC [BPRG] +1.99%
IOMED INC [IOX] +1.79%

Drug Manufacturers

EXEGENICS INC [EXEG.OB] +30.16%
YM BIOSCIENCES INC [YMI] +6.80%
ADVANCIS PHARMA CP [AVNC] +3.69%
DUSA PHARM INC [DUSA] +3.68%
NEUROCHEM INC [NRMX] +3.43%

Drug Related Products

XELR8 HOLDINGS, INC [BZI] +5.33%
NATROL INC [NTOL] +3.38%
PERRIGO COMPANY [PRGO] +1.56%
ZILA INC [ZILA] +0.90%
DRAXIS HEALTH INC [DRAX] +0.64%

Generic Drugs

MYLAN LABS INC [MYL] +5.24%
PHARMACUTICAL CO [PRX] +1.69%
CATALYST PHARMACEUTI [CPRX] +0.49%

Medical Appliances & Equipment

ARRHYTHMIA RES TECH [HRT] +4.07%
CHAD THERAPEUTICS [CTU] +3.36%
ACCURAY INCORPORATED [ARAY] +2.79%
HANSEN MEDICAL, INC. [HNSN] +2.25%
REGENERATION TECH [RTIX] +2.20%

Medical Instruments & Supplies

MICROMED CARDIOVASCU [MMCV.OB] +5.00%
FOXHOLLOW TECH INC [FOXH] +4.84%
ANGIODYNAMICS INC [ANGO] +3.86%
QUANTRX BIOMEDICAL [QTXB.OB] +3.85%
IMPLANT SCIENCES CP [IMX] +3.47%

Medical Laboratories & Research

SPHERIX INC [SPEX] +7.42%
GENOMIC HEALTH, INC. [GHDX] +4.05%
MEDASORB TECHNOLOGS [MSBT.OB] +3.51%
NEOGENOMICS INC [NGNM.OB] +1.97%
ALLIANCE IMAGING INC [AIQ] +1.47%

http://www.biohealthinvestor.com/

Buffett Missed These Two…

Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.

But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.

Unlock the two dividend legends Buffett missed in this new free report.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.